Lasa Supergenerics Limited (BOM:540702)

Market Cap	621.26M
Revenue (ttm)	1.47B
Net Income (ttm)	-147.57M
Shares Out	n/a
EPS (ttm)	-2.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,658
Average Volume	44,808
Open	13.25
Previous Close	13.00
Day's Range	12.74 - 13.25
52-Week Range	8.52 - 33.49
Beta	n/a
RSI	53.68
Earnings Date	Aug 12, 2025

About Lasa Supergenerics

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, and halquinol, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2016
• Employees: 77
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540702

Financial Performance

In 2024, Lasa Supergenerics's revenue was 1.47 billion, an increase of 41.23% compared to the previous year's 1.04 billion. Losses were -147.57 million, -32.09% less than in 2023.